Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 809Precursor Cell Lymphoblastic Leukemia-Lymphoma 171Recurrence 141Neoplasms, Plasma Cell 111Lymphoma 93Leukemia 91Neoplasms 81Burkitt Lymphoma 57Vomiting 51Lymphoma, Non-Hodgkin 50Immunoglobulin Light-chain Amyloidosis 50Lymphoma, Large B-Cell, Diffuse 44Nausea 38Lymphoma, Mantle-Cell 38Prostatic Neoplasms 31Lymphoma, Follicular 30Hodgkin Disease 29Waldenstrom Macroglobulinemia 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 26Leukemia, Lymphocytic, Chronic, B-Cell 26Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Breast Neoplasms 25Lung Neoplasms 23Amyloidosis 21Leukemia, Biphenotypic, Acute 18Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Extranodal NK-T-Cell 16Smoldering Multiple Myeloma 15

Interventions

Dexamethasone 4Electroencephalography 3XENP 1595 2Methods 2selinexor 1pomalidomide 1ixazomib 1fasudil 1birtamimab 1UE2343 1Transurethral Resection of Bladder 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Rosiglitazone 1Propofol 1Positron-Emission Tomography 1Neurofeedback 1Methotrexate 1Melphalan 1Mass Screening 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hypnosis 1Hormones 1Exercise 1Ethanol 1Drug Delivery Systems 1Donepezil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Alzheimer Disease × Dexamethasone × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT04984330 2022-11-17

STARR

Weill Medical College of Cornell University

Phase EARLY_PHASE1 Withdrawn
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

NCT03236792 2022-09-29

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
28 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡